Chakma Justin
SEC CIK 1951238 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | Chief Business Off | 136.4K | — | $8.56M | 12 | 2022-11-08 | 2025-11-12 |
Most active insiders at SPRY, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chakma Justin | Chief Business Off | — | $1.48M |
| 2 | Karas Eric | Chief Commercial Off | — | $250.0K |
| 3 | Dorsey Brian | COO | — | $190.1K |
| 4 | Fitzpatrick Alexander A | CLO | — | $33.5K |
| 5 | Shah Pratik | Dir | — | — |
Transactions 12
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-14 | 2025-11-12 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale+OE | $8.87 | -166.4K | 136.4K | -55% | -$1.48M |
| D | 2025-11-14 | 2025-11-12 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +30.0K | 166.4K | +22% | +$25.2K |
| DM | 2024-12-13 | 2024-12-12+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale+OE | $12.23 | -144.6K | 136.4K | -51% | -$1.77M |
| DM | 2024-12-13 | 2024-12-12+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | M - OptEx | $0.9532 | +144.6K | 253.7K | +133% | +$137.8K |
| D | 2024-12-12 | 2024-12-10 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +50.0K | 186.4K | +37% | +$42.0K |
| D | 2024-12-12 | 2024-12-10 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale+OE | $13.15 | -50.0K | 136.4K | -27% | -$657.5K |
| DM | 2024-12-06 | 2024-12-04+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +144.6K | 181.4K | +394% | +$121.5K |
| DM | 2024-12-06 | 2024-12-04+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale+OE | $14.11 | -144.6K | 136.4K | -51% | -$2.04M |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale+OE | $13.43 | -90.0K | 136.4K | -40% | -$1.21M |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | M - OptEx | $0.84 | +90.0K | 181.4K | +98% | +$75.6K |
| M | 2024-11-27 | 2024-11-25+ | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | S - Sale | $14.12 | -100.0K | 136.4K | -42% | -$1.41M |
| D | 2022-11-10 | 2022-11-08 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Chief Business Off | A - Grant | — | +236.4K | 236.4K | New | — |
Purchase Sale Sale after option exercise All abbreviations